Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Eltrombopag (SB-497115, GlaxoSmithKline) is a new, small-molecule, nonpeptide, oral platelet growth factor that acts as a thrombopoietin-receptor agonist.

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

SAN DIEGO — Eltrombopag conferred a higher rate of durable platelet response in the absence of rescue treatments than standard first-line treatments for children with newly diagnosed immune ...

However, eltrombopag and romiplostim should never be considered as front-line treatment of the disease, George said. “These drugs are very expensive and they are maintenance therapies,” he said.

Eltrombopag (Promacta) is an oral thrombopoietin mimetic that binds to c-MPL, promoting megakaryopoiesis and release of platelets from mature megakaryocytes. 12 Eltrombopag increases platelet ...